Impact of Modeling & Simulation in Drug Development
Rosa’s Worldwide Webinar Series fosters the adoption of modeling and simulation by informing a broad audience about the strategic impact it can have on all aspects of research and development.
Since its inception in 2011, this complimentary monthly series has featured select speakers from academia, industry, Rosa client companies, and Rosa itself. The series has drawn many thousands of attendees worldwide from all drug development disciplines.
PLEASE NOTE - ***ALL WEBINARS PRIOR to 2017*** are available by contacting usCLICK HERE
Sign up to receive Webinar and QSP News Alerts
Date
Presenter / Topic
Register
Alvaro Ruiz-Martinez, PhD, Senior Modeler, Rosa & Co. LLC
Dr. Alvaro Ruiz-Martinez has twelve years of computational and modeling experience related to mechanical, chemical, and biological systems. He has developed models focused on immuno-oncology, biopolymer assembly, and pharmacokinetics and pharmacodynamics. Dr. Ruiz-Martinez received his Ph.D. in Mechanical Engineering from the University of California, San Diego, and his postdoctoral degree from Johns Hopkins University.
A Reusable PBPK–QSP Platform for AAV and LNP Gene Therapy: Getting Dose and Tissue Targeting Right
Emily Nieves, Co-founder and CEO, Delineate Inc., Cambridge, MA
Emily Nieves holds a Bachelor of Science in Biological Engineering from the University of Georgia, where she conducted research in Dr. Melissa Hallow's Quantitative Systems Pharmacology lab. Her professional experience includes the development of Quantitative Systems Pharmacology and machine learning models across diverse therapeutic areas, including the cardiorenal system, metabolism, and cell-based therapies, with contributions at Pfizer and AstraZeneca.
As a former PhD candidate in Biological Engineering at MIT, Emily specialized in hybrid AI and scientific machine learning algorithms. She currently serves as Co-Founder and CEO of Delineate, a seed-stage company that collaborates with pharmaceutical organizations to leverage large language models and artificial intelligence technologies in advancing Model Informed Drug Development workflows.
Leveraging GenAI for the automation of Model Based Meta Analysis (MBMA)
Irina Kareva, Associate Director in Quantitative Pharmacology, EMD Serono (US business of Merck KGaA), Boston, MA
Irina Kareva received her PhD in Applied Mathematics for Life and Social Sciences from Arizona State University in 2012. Her research has been focused on mathematical modeling of cancer as an evolving ecological system, with particular focus on applying insights from ecology and evolution to understanding cancer initiation and progression. She did her post-doctoral fellowship at Tufts Medical Center in Boston, prior to joining EMD Serono (US business of Merck KGaA) in 2016, where she is currently an Associate Director in Quantitative Pharmacology Department. Dr. Kareva has co-authored 3 books and over 50 publications, and conducts both applied and basic research. Her current work is focused primarily on fit-for-purpose mechanistic modeling of compounds in immunology and immuno-oncology to enable rational safe and efficacious First-in-Human (FIH) dose projections both for monotherapy and combination therapy.
Guiding model-driven combination dose selection using multi-objective synergy optimization
